Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0PL4F
|
|||
| Former ID |
DNC006893
|
|||
| Drug Name |
GW-3965
|
|||
| Synonyms |
GW3965; 405911-09-3; GW 3965; UNII-6JI5YOG7RC; GW-3965; 6JI5YOG7RC; CHEMBL59030; CHEBI:79995; (3-{3-[[2-CHLORO-3-(TRIFLUOROMETHYL)BENZYL](2,2-DIPHENYLETHYL)AMINO]PROPOXY}PHENYL)ACETIC ACID; 2-[3-[3-[[2-chloro-3-(trifluoromethyl)phenyl]methyl-[2,2-di(phenyl)ethyl]amino]propoxy]phenyl]acetic acid; [3-(3-{[2-Chloro-3-(Trifluoromethyl)benzyl](2,2-Diphenylethyl)amino}propoxy)phenyl]acetic Acid; GW-3965A; 3-(3-[[2-chloro-3-(trifluoromethyl)benzyl)(2,2-diphenylethyl)-amino]-propoxy}-phenyl acetic acid; GW 3965A
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Major depressive disorder [ICD-11: 6A70.3; ICD-10: F32.2] | Investigative | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C33H31ClF3NO3
|
|||
| Canonical SMILES |
C1=CC=C(C=C1)C(CN(CCCOC2=CC=CC(=C2)CC(=O)O)CC3=C(C(=CC=C3)C(F)(F)F)Cl)C4=CC=CC=C4
|
|||
| InChI |
1S/C33H31ClF3NO3/c34-32-27(15-8-17-30(32)33(35,36)37)22-38(18-9-19-41-28-16-7-10-24(20-28)21-31(39)40)23-29(25-11-3-1-4-12-25)26-13-5-2-6-14-26/h1-8,10-17,20,29H,9,18-19,21-23H2,(H,39,40)
|
|||
| InChIKey |
NAXSRXHZFIBFMI-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 405911-09-3
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
829748, 7885550, 10300132, 14911410, 17396621, 26755460, 36889920, 46519987, 53787809, 57404840, 78372800, 85788706, 92728670, 93578094, 103249137, 104638678, 124892359, 127337902, 127337903, 127337904, 134344098, 135325764, 135650333, 136367927, 136946547, 137183401, 139769446, 144115385, 144116041, 151995567, 152258261, 160647097, 171578606, 172650060, 172659554, 179317066, 185989924, 198939615, 223397282, 223445164, 223943816, 228248894, 241080729, 247228919, 252215521
|
|||
| ChEBI ID |
CHEBI:79995
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Oxysterols receptor LXR-alpha (NR1H3) | Target Info | Inhibitor | [2] |
| Oxysterols receptor LXR-beta (NR1H2) | Target Info | Inhibitor | [2] | |
| KEGG Pathway | PPAR signaling pathway | |||
| Non-alcoholic fatty liver disease (NAFLD) | ||||
| Hepatitis C | ||||
| Pathway Interaction Database | RXR and RAR heterodimerization with other nuclear receptor | |||
| Reactome | Nuclear Receptor transcription pathway | |||
| WikiPathways | SREBP signalling | |||
| Nuclear Receptors | ||||
| Nuclear Receptors in Lipid Metabolism and Toxicity | ||||
| Nuclear Receptors Meta-Pathway | ||||
| PPAR Alpha Pathway | ||||
| Liver X Receptor Pathway | ||||
| Adipogenesis | ||||
| SREBF and miR33 in cholesterol and lipid homeostasis | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Liver X receptor in the hippocampus: A potential novel target for the treatment of major depressive disorder Neuropharmacology. 2018 Jun;135:514-528. | |||
| REF 2 | Indazole-based liver X receptor (LXR) modulators with maintained atherosclerotic lesion reduction activity but diminished stimulation of hepatic tr... J Med Chem. 2008 Nov 27;51(22):7161-8. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.